Form 4: Astria Therapeutics CFO Noah Clauser Reports Stock Option Grant

Noah Clauser, CFO of Astria Therapeutics, reports the acquisition of stock options.

Summary

• On March 21, 2025, Noah Clauser, the Chief Financial Officer of Astria Therapeutics, Inc., was granted stock options to purchase 262,500 shares of common stock at an exercise price of $6.41.
• The options vest over a four-year period, with 25% vesting on the first anniversary of February 13, 2025, and the remainder vesting in equal monthly installments over the following three years.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options is a standard practice and generally viewed as a positive incentive for management.

Positives

• The grant of stock options to the CFO aligns his interests with those of the shareholders, incentivizing him to improve the company's performance.

Industry Context

Stock option grants are a common practice in the biotechnology industry to incentivize key executives and align their interests with the long-term success of the company. This is a standard compensation component.

Comparison to Industry Standards

• Stock option grants are a typical component of executive compensation packages in the biotech industry.
• The size of the grant is likely determined by factors such as the executive's role, company size, and overall compensation strategy.
• Comparable companies in the biotech sector often use similar equity-based compensation to attract and retain talent.

Stakeholder Impact

• Shareholders may view the stock option grant as a positive sign, aligning management's interests with the company's long-term success.
• Employees may see this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

stock options, Astria Therapeutics, CFO, Noah Clauser, Form 4, ATXS, vesting